diabetestalk.net

Metformin Duo

Xigduo Xr (dapagliflozin And Metformin Hcl Extended-release Tablets): Side Effects, Interactions, Warning, Dosage & Uses

Xigduo Xr (dapagliflozin And Metformin Hcl Extended-release Tablets): Side Effects, Interactions, Warning, Dosage & Uses

(dapagliflozin and metformin HCl) Extended-Release Tablets Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels ( > 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL [see WARNINGS AND PRECAUTIONS ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS , DRUG INTERACTIONS , and Use in Specific Populations ]. If metformin-associated lactic acidosis is suspected, immediately discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see WARNINGS AND PRECAUTIONS ]. XIGDUO XR (dapagliflozin and metformin HCl)extended-release tablets contain two oral antihyperglycemic medications usedin the management of type 2 diabetes : dapagliflozin and metforminhydrochloride. Dapagliflozin is described chemic Continue reading >>

Xigduo Xr (dapagliflozin/metformin) Dosing, Indications, Interactions, Adverse Effects, And More

Xigduo Xr (dapagliflozin/metformin) Dosing, Indications, Interactions, Adverse Effects, And More

Individualize starting dose based on patients current therapy Take once daily in morning with food, with gradual dose escalation to reduce the adverse GI effects due to metformin Adjust dose based on effectiveness and tolerability; not to exceed daily dose of dapagliflozin 10 mg and metformin 2000 mg (ie, 2 tablets of 5mg/1000mg) Patients taking an evening dose of metformin XR should skip their last dose before starting dapagliflozin/metformin the following morning eGFR 30-45 mL/min/1.73 m: Not recommended to initiate treatment Monitor eGFR at least annually or more often for those at risk for renal impairment (eg, elderly) If eGFR falls below 45mL/min/1.73 m while taking metformin, risks and benefits of continuing therapy should be evaluated If eGFR falls below 30 mL/min/1.73 m: while taking metformin, discontinue the drug Correct volume depletion before initiating in patients not previously treated with dapagliflozin Not for type 1 diabetes mellitus or diabetic ketoacidosis eGFR 30-60 mL/min (8-28.3%; placebo 6.5-16.1%) Age 65 yr and eGFR 30-60 mL/min (7-35.1%; placebo 4.9-19.1%) Female genital mycotic infections (6.9-8.4%) Male genital mycotic infections (2.7-2.8%) Patients on loop diuretics (0-9.7%; 1.8-2.5%) Patients with moderate renal impairment, GFR 30-60 mL/min (0.9-1.9%; placebo 1.5-1.9%) Acute kidney injury and impairment in renal function Cholestatic, hepatocellular, and mixed hepatocellular liver injury Lactic acidosis caused by metformin accumulation (plasma concentration >5 mcg/mL) is a rare but potentially severe consequence; if it occurs, mortality is ~50% Risk increases with certain conditions (eg, renal impairment, sepsis, dehydration, excess alcohol intake, hepatic impairment, and acute CHF) Onset is subtle, accompanied only by nonspecific symptoms Continue reading >>

Xigduo Xr 5/1000 (extended Release Tablets)

Xigduo Xr 5/1000 (extended Release Tablets)

Xigduo XR 5/1000 (Extended release tablets) Xigduo XR 5/1000 (Extended release tablets) Xigduo XR 5/1000 (Extended release tablets) Consumer medicine information (CMI) leaflet Please read this leaflet carefully before you start using Xigduo XR 5/1000 (Extended release tablets). Download CMI (PDF) Download large text CMI (PDF) This leaflet answers some common questions about XIGDUO XR. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking XIGDUO XR against the benefits they expect it will have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. XIGDUO XR is a prescription medicine used with diet, exercise and sometimes other medicines such as insulin, a sulfonylurea, or a dipeptidyl peptidase (DPP-4) inhibitor to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus. Type 2 diabetes mellitus (also called non-insulin-dependent diabetes mellitus, or NIDDM) is the condition of having high levels of blood sugar (hyperglycaemia). This is usually because your body does not make enough insulin and /or the insulin that your body produces does not work as well as it should. Left uncontrolled, the build-up of high levels of sugar in your blood can lead to serious medical problems. The main goal of treating type 2 diabetes is to control your blood sugar to a normal level. Lowering and controlling blood sugar may help prevent or delay complications of diabetes, which include kidney disease, blindness and amputation. XIGDUO XR contains two active ingredients, dapagliflozin and metformin hydrochloride. Dapagliflozin is a member of a class of medicines you take by Continue reading >>

Dailymed - Xigduo Xr- Dapagliflozin And Metformin Hydrochloride Tablet, Film Coated, Extended Release

Dailymed - Xigduo Xr- Dapagliflozin And Metformin Hydrochloride Tablet, Film Coated, Extended Release

See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. ( 5.1 ) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. ( 5.1 ) If lactic acidosis is suspected, discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. ( 5.1 ) Dosing and Administration ( 2.1 )7/2017 Warnings and Precautions ( 5 )3/2017 XIGDUO XR is a combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. (1) Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis. (1.1) Increased LDL-C: Monitor and treat per standard of care. ( 5.9 ) Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials. Dapagliflozin should not be used in patients with active bladder cancer and should be used with caution in patients with a prior history of bladder cancer. ( 5.10 ) Macr Continue reading >>

Pharmaceutical Field - Trajenta And Metformin Are Effective Diabetes Duo

Pharmaceutical Field - Trajenta And Metformin Are Effective Diabetes Duo

Trajenta and metformin are effective diabetes duo A combination of a branded drug from Boehringer Ingelheim and Eli Lilly and a drug widely available in generic form has been shown in a phase III trial to be effective in treating type 2 diabetes. Boehringer and Lillys Trajenta (linagliptin) in combination with metformin was shown to be more effective in controlling blood glucose levels than metformin alone. Metformin, a successful glucophage drug for control of type 2 diabetes, was developed by Bristol-Myers Squibb and is now available in multiple branded and generic formulations. Both drugs are used as monotherapies for type 2 diabetes in the UK, and some doctors already prescribe them together; but the new findings are likely to make the combination a standard treatment option. The 24-week trial, part of a wider phase III study of the combination, showed that poorly controlled patients who received both drugs achieved an average reduction of 3.7% in HbA1c. The drug combination was well tolerated, with only 9% of patients suffering side-effects and only 1.5% suffering hypoglycaemic events. A previous one-year monotherapy trial had shown Trajenta to be of similar efficacy to glimepiride but with a significantly lower risk of side-effects, hypoglycaemic events and weight gain. Trajenta is also the only approved diabetes medication with no need for dose adjustment in adult patients. Professor Klaus Dugi, Corporate Senior VP of Medicine at Boehringer Ingelheim, said: Many patients with high HbA1c levels require more than metformin alone to reach their blood glucose targets. Linagliptin can support patients with type 2 diabetes to effectively manage their condition. To voice your opinion, please Log in or Register . You are a really great author. Wish you lots of success i Continue reading >>

Xigduo Xr New Fda Drug Approval | Centerwatch

Xigduo Xr New Fda Drug Approval | Centerwatch

Xigduo XR is a combination of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride extended-release, a biguanide. SGLT2 inhibitors remove glucose from the body via the kidneys. Xigduo XR is specifically indicatedas an adjunct therapy to diet and exercise to improve glycemic control in adults with type II diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. Xigduo XR is supplied as a tablet for oral administration. The starting dose should be individualized based on each patients current treatment regimen. The maximum daily recommended dose is 10 mg for dapagliflozin and 2,000 mg for metformin HCl. Xigduo XR should be taken once daily in the morning with food with gradual dose escalation to reduce the risk of gastrointestinal side effects due to metformin. The FDA approval of Xigduo XR was based on four Phase III clinical trials, which provided clinical evidence for the efficacy and safety of dapagliflozin and metformin IR or XR tablets in treatment-nave patients, in patients inadequately controlled on metformin, as well as compared to a sulfonylurea (glipizide) plus metformin. There have been no clinical studies conducted with Xigduo XR combination tablets. Bioequivalence was demonstrated in healthy adults between Xigduo XR and dapagliflozin plus metformin XR as separate tablets. Adverse reactions associated with the use of Xigduo XR may include, but are not limited to, the following: Xigduo XR combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet. SGLT2 inhibitors are a class of medicines that remove gl Continue reading >>

New Study Showed Significant Reduction In Blood Glucose With Linagliptin Alone And In Combination With Metformin In Adults Newly Diagnosed With Type 2 Diabetes

New Study Showed Significant Reduction In Blood Glucose With Linagliptin Alone And In Combination With Metformin In Adults Newly Diagnosed With Type 2 Diabetes

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes • Study showed significant reductions of HbA1c up to 2.8 percent  in treatment-naïve adults with uncontrolled Type 2 Diabetes and marked hyperglycaemia (HbA1c >8.5 percent) • Linagliptin monotherapy and in combination with metformin was well tolerated with no significant adverse events • No weight gain seen with linagliptin monotherapy; average weight loss of 1.1kg seen in combination therapy with metformin Ingelheim, Germany and Indianapolis, US, 03 December 2013 – Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D). The result showed that linagliptin as monotherapy or in initial combination with metformin achieved clinically significant improvements in glucose control in patients with newly diagnosed T2D and marked hyperglycaemia. Results also showed both treatments provided statistically significant reductions in blood glucose levels, with the combination therapy having greater glucose reduction compared to monotherapy. The results were presented during the 2013 World Diabetes Congress, which is being held 2-6 December in Melbourne, Australia. The study randomised 316 adults with a mean average plasma glucose concentration (HbA1c) of 9.8 percent to receive linagliptin 5 mg once-daily (n = 157) and the initial combination of linagliptin 5 mg once-daily plus metformin twice-daily (uptitrated to a maximal dose of 2000 mg/d; n = 159) for 24 weeks. The results show Continue reading >>

New Metformin Combination Medicine Approved For Type 2 Diabetes

New Metformin Combination Medicine Approved For Type 2 Diabetes

On October 30, the US Food and Drug Administration (FDA) approved the combination oral diabetes drug Xigduo XR for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. The medicine, a development of AstraZeneca, combines dapagliflozin (brand name Farxiga), an SGLT2 inhibitor, and extended-release metformin (Glucophage XR and others). In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main proteins responsible for this reabsorption is SGLT2. By inhibiting the action of SGLT2, Farxiga blocks the reabsorption of glucose by the kidneys, promoting a loss of glucose in the urine and lowering blood glucose levels. Metformin works by decreasing the amount of glucose made by the liver and by improving insulin sensitivity in the liver, muscle, and fat cells. Xigduo XR, the first once-daily combination tablet of an SGLT2 inhibitor and extended-release metformin approved in the United States, will be offered in doses of 5 milligrams of dapagliflozin/500 milligrams of metformin, 5 milligrams of dapagliflozin/1,000 milligrams of metformin, 10 milligrams of dapagliflozin/500 milligrams of metformin, and 10 milligrams of dapagliflozin/1,000 milligrams of metformin to be taken once a day in the morning with food. This medicine should not be used in people with Type 1 diabetes, diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body), or moderate to severe kidney impairment. Because of the inclusion of metformin, Xigduo XR carries the risk of a rare but serious metabolic complication known as lactic acidosis. The most commonly reported side effects of Farxiga plus metformin compared to placebo (inactive treatment) plus metfo Continue reading >>

Xigduo Xr Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - Webmd

Xigduo Xr Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - Webmd

Headache , diarrhea , nausea , vomiting , runny nose , or sore throat may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. If stomach symptoms return later (after taking the same dose for several days or weeks), tell your doctor right away. Stomach symptoms that occur after the first days of your treatment may be signs of lactic acidosis . An empty tablet shell may appear in your stool. This effect is harmless because your body has already absorbed the medication . Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: signs of a urinary tract infection (such as burning/painful/frequent/urgent urination, pink/bloody urine), signs of kidney problems (such as change in the amount of urine, swelling legs/feet). Use of this medication may result in a new yeast infection in the vagina or penis . You are more likely to get a yeast infection if you have had yeast infections in the genital area before. Uncircumcised men are also at an increased risk for infections. Tell your doctor right away if you have signs of yeast infection in the vagina (such as unusual vaginal discharge /burning/ itching /odor) or in the penis (such as redness/ itching /swelling of the penis, unusual discharge from the penis). Your doctor may direct you to use nonprescription antifungal products to treat these infections. Tell your doctor if your condition persists or worsens after treatment. This medication does not usually cause low blood sugar ( hypoglycemia ). Low blood sugar may occur if this drug is prescribed with oth Continue reading >>

A Treatment For Adults With Type 2 Diabetes Mellitus, In Addition To Diet And Exercise. Xigduo Xr Is Not Recommended For Patients With Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis.

A Treatment For Adults With Type 2 Diabetes Mellitus, In Addition To Diet And Exercise. Xigduo Xr Is Not Recommended For Patients With Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis.

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL. Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. If lactic acidosis is suspected, discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. Contraindications Warnings and Precautions Hypotension: Dapagliflozin causes intravascular volume contraction, and symptomatic hypotension can occur. Assess and correct volume status before initiating XIGDUO XR in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for hypotension. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes receiving dapagliflozin. Some cases were fatal. Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue XIGDUO XR, evaluate and treat promptly. Before initiating XIGDUO XR, consider risk factors for ketoacidosis. Patients on XIGDUO XR may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. Acute Kidney Injury and Impai Continue reading >>

Xigduo Xr (dapagliflozin/metformin Hydrochloride) Dose, Indications, Adverse Effects, Interactions... From Pdr.net

Xigduo Xr (dapagliflozin/metformin Hydrochloride) Dose, Indications, Adverse Effects, Interactions... From Pdr.net

Xigduo XR Oral Tab ER: 10-1000mg, 10-500mg, 2.5-1000mg, 5-1000mg, 5-500mg For the treatment of type 2 diabetes mellitus in combination with diet and exercise. Individualize the dose based on efficacy and tolerability. Give dose PO once daily in the morning with food. CURRENTLY TAKING DAPGLIFLOZIN: Initiate at the dose that contains metformin 500 mg with a similar total daily dose of dapagliflozin; increase the dose gradually to reduce the GI side effects due to metformin. In older patients, use a conservative initial and maintenance dose of metformin due to the potential for decreased renal function; carefully assess renal function before dose selection. CURRENTLY TAKING METFORMIN: In patients currently treated with metformin, initiate at the dose containing dapagliflozin 5 mg with a similar total daily dose of metformin. For patients requiring a dose of 5 mg dapagliflozin with 2,000 mg metformin, use 2 of the dapagliflozin 2.5 mg/metformin 1,000 mg XR tablets PO once daily. Patients taking an evening dose of metformin XR should skip their last dose before starting dapagliflozin; metformin. Correct volume depletion prior to initiation of dapagliflozin. CURRENTLY TAKING BOTH DRUGS: May switch to combination product using the same total daily doses of each component. For patients requiring a dose of 5 mg dapagliflozin with 2,000 mg metformin, use 2 of the dapagliflozin 2.5 mg/metformin 1,000 mg XR tablets PO once daily. Max: metformin 2,000 mg/day and dapagliflozin 10 mg/day PO. Dapagliflozin 10 mg/day PO and metformin 2000 mg/day PO. Dapagliflozin 10 mg/day PO and metformin 2000 mg/day PO. Safety and efficacy have not been established. Safety and efficacy have not been established. Avoid use in patients with clinical or laboratory evidence of hepatic disease as there is Continue reading >>

Xigduo (dapagliflozin, Metformin)

Xigduo (dapagliflozin, Metformin)

What is Xigduo used for? Xigduo tablets are licensed for use in people with type 2 diabetes whose blood sugar is not controlled by the maximum tolerated dose of metformin alone or who are already taking metformin and dapagliflozin as separate tablets. Xigduo tablets can also be used for people with type 2 diabetes whose blood sugar is not sufficiently controlled by other antidiabetic medicines. It can be added to treatment with a sulphonylurea such as gliclazide or glibenclamide, or to treatment with insulin. How does Xigduo work? In type 2 diabetes the cells in the body become resistant to the action of insulin. Insulin is the main hormone responsible for controlling the level of sugar (glucose) in the blood. It makes cells in the body remove sugar from the blood. When the cells are resistant to insulin this makes blood sugar levels rise too high. Metformin is a type of antidiabetic medicine known as a biguanide. It works in a number of ways to decrease the amount of sugar in the blood. Firstly, it reduces the amount of sugar produced by cells in the liver. Secondly, it increases the sensitivity of muscle cells to insulin. This enables these cells to remove sugar from the blood more effectively. Finally, it delays absorption of sugar from the intestines into the bloodstream after eatingso that there is less of a spike in blood sugar levels after meals. Dapagliflozin works in the kidneys, where it allows the body to excrete excess glucose from the blood into the urine. Normally, when the kidneys filter and clean the blood, glucose is filtered out of the blood at the same time. The glucose is then reabsorbed back into the blood by a mechanism called the sodium-glucose co-transporter 2 (SGLT2). The kidneys normally reabsorb glucose back into the blood even when the levels Continue reading >>

Jardiance Duo Dosage & Drug Information | Mims.com Philippines

Jardiance Duo Dosage & Drug Information | Mims.com Philippines

Per 5 mg/500 mg FC tab Empagliflozin 5 mg, metformin HCl 500 mg. Per 5 mg/1 g FC tab Empagliflozin 5 mg, metformin HCl 1 g. Per 12.5 mg/500 mg FC tab Empagliflozin 12.5 mg, metformin HCl 500 mg. Per 12.5 mg/1 g FC tab Empagliflozin 12.5 mg, metformin HCl 1 g Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM: when treatment w/ both empagliflozin & metformin is appropriate; inadequately controlled w/ metformin or empagliflozin alone; inadequately controlled w/ empagliflozin or metformin in combination w/ other glucose-lowering products including insulin; already treated w/ empagliflozin & metformin co-administered as separate tab. Adults w/ type 2 DM & established CV disease to reduce the risk of CV death, in conjunction w/ other measures to reduce CV risk in line w/ the current standard care. Click to view detailed Jardiance Duo Indications/Uses 1 tab bid. Individualized dose. Max daily dose: 25 mg/2,000 mg. Patient not adequately controlled on metformin alone or in combination w/ other products including insulin Empagliflozin 5 mg bid + metformin dose already being taken. Patient tolerating a total daily dose of empagliflozin 10 mg May be increased to empagliflozin 25 mg total daily dose. Patient already treated w/ empagliflozin Continue to take the same empagliflozin daily dose. Patient switching from separate tab of empagliflozin (10 mg or 25 mg total daily dose) & metformin Take the same daily dose of empagliflozin & metformin already being taken or the nearest therapeutically appropriate dose of metformin. Renal impairment [eGFR 45-59 mL/min/1.73 m2 or CrCl 45-59 mL/min (in the absence of other conditions that may increase risk of lactic acidosis)] Max: Metformin 500 mg bid. View Jardiance Duo overdosage for action to be taken in the ev Continue reading >>

Xigduo Xr: Uses, Dosage & Side Effects - Drugs.com

Xigduo Xr: Uses, Dosage & Side Effects - Drugs.com

Generic Name: dapagliflozin and metformin (DAP a gli FLOE zin and met FOR min) Xigduo XR extended release tablets contain a combination of dapagliflozin and metformin . Dapagliflozin and metformin are oral diabetes medicines that help control blood sugar levels. Dapagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Metformin lowers glucose production in the liver and also causes your intestines to absorb less glucose. Xigduo XR is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus . Xigduo XR is not for treating type 1 diabetes. Men's Health Month And Movember: Raising The Profile Of Men's Health One Stache At A Time You should not use Xigduo XR if you have moderate to severe kidney disease, if you are on dialysis, or if you have metabolic acidosis. Xigduo XR is not for treating type 1 diabetes. If you need to have any type of x-ray or CT scan using a dye that is injected into your veins, you will need to temporarily stop taking Xigduo XR. Xigduo XR may cause a serious condition called lactic acidosis. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, slow or uneven heart rate, dizziness, or feeling very weak or tired. You should not use Xigduo XR if you are allergic to dapagliflozin (Farxiga) or metformin (Glucophage, Actoplus Met, Avandamet, Glucovance, Jentadueto, Kombiglyze, Metaglip, and others), or if you have: moderate to severe kidney disease (or if you are on dialysis); or metabolic acidosis or diabetic ketoacidosis (call your doctor for treatment). If you need to have any type of x-ray or CT scan using a dye that is injected into your Continue reading >>

Dapagliflozin And Saxagliptin Make A Dazzling Duo

Dapagliflozin And Saxagliptin Make A Dazzling Duo

Dapagliflozin and Saxagliptin Make a Dazzling Duo Home Blog Anti-Diabetic Dapagliflozin and Saxagliptin Make a Dazzling Duo Dapagliflozin and Saxagliptin Make a Dazzling Duo The latest news in the fight against type 2 diabetes highlights Dapagliflozin and Saxagliptin as the latest dazzling duo. Known as the brand name medications Farxiga {Dapagliflozin} and Onglyza {Saxagliptin} these powerhouse drugs have proven themselves in Phase lll trials. Data recently released from the 534 patient, three-arm trial demonstrated that the combination treatment of Dapagliflozin and Saxagliptin, alongside Metformin was superior to either Dapagliflozin and Metformin or Saxagliptin and Metformin adjunctively. The 24 week Phase lll trial involved patients who were not gleaning adequate control of their blood sugar from metformin only. Results were telling in the patient population who received Dapagliflozin, Saxagliptin and Metformin, with more patients achieving their blood sugar goal of less than 7% HbA1c by the conclusion of the trial. The HbA1c on average dropped 1.47 percent in the patients who were dosed with metformin and the dynamic diabetes duo. The use of the DPP-4 inhibitor Saxagliptin, alongside the SGLT-2 inhibitor Dapagliflozin appears to be an effectual treatment option for patients who have difficulty obtaining optimal blood sugar control. The FDA approved Dapagliflozin for the treatment of type 2 diabetes mellitus on January 13, 2014 as a once daily oral medication. The typical starting dose for most patients is 5 milligrams of Dapagliflozin, taken once daily, but some patients may need up to 10 milligrams once a day to achieve blood sugar control. Two dozen comprehensive clinical trials of Dapagliflozin have taken place with over than 11,000 patients who suffer from ty Continue reading >>

More in diabetes